To date there has been no general consensus regarding the effectiveness of N-acetylcysteine as a protective therapy against contrast medium-induced nephropathy. Several phase III clinical trials have been conducted without a proper understanding of N-acetylcysteine pharmacology, particularly with regard to first-pass hepatic metabolism. A review was conducted of the literature concerning contrast medium-induced nephropathy and new studies of human N-acetylcysteine pharmacology were performed. After an analysis was performed, it was concluded that further phase I and phase II trials are needed. The efficacy of N-acetylcysteine in the prevention of contrast medium-induced nephropathy may be demonstrated with the use of higher doses than used in earlier studies, in combination with parenteral administration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvir.2007.11.003DOI Listing

Publication Analysis

Top Keywords

contrast medium-induced
16
medium-induced nephropathy
16
phase iii
8
n-acetylcysteine pharmacology
8
n-acetylcysteine
5
n-acetylcysteine prevent
4
contrast
4
prevent contrast
4
medium-induced
4
nephropathy
4

Similar Publications

Age and Vasodilator Response to Different Hyperemic Agents: Adenosine versus Contrast Medium.

Rev Cardiovasc Med

July 2024

Diagnostic, Interventional and Acute Cardiac Care Unit, Ospedale Isola Tiberina - Gemelli Isola, 00186 Rome, Italy.

Background: Age-related remodelling has the potential to affect the microvascular response to hyperemic stimuli. However, its precise effects on the vasodilatory response to adenosine and contrast medium, as well as its influence on fractional flow reserve (FFR) and contrast fractional flow reserve (cFFR), have not been previously investigated. We investigate the impact of age on these indices.

View Article and Find Full Text PDF

Purpose: To summarize identified risk factors, the most common clinical presentations, radiological and neurophysiological features, and proposed pathophysiological mechanisms of contrast medium-induced transient cortical blindness (TCB).

Methods: A systematic search of PubMed, Cochrane Central Register of Controlled Trials, and clinicaltrials.gov was performed.

View Article and Find Full Text PDF

Production of Ochratoxin A and Citrinin and the Expression of Their Biosynthetic Genes from in Liquid Culture.

ACS Omega

May 2024

Metrology, National Research Council, 1200 Montreal Road, Ottawa, Ontario K1A 0R6, Canada.

is a fungal pathogen capable of producing two mycotoxins of concern, ochratoxin A (OTA) and citrinin (CIT). The production profile of these two mycotoxins is not well understood but could help mitigate co-contamination in the food supply. As such, the production of OTA and CIT from DAOMC 242724 was investigated under different growing conditions in liquid culture.

View Article and Find Full Text PDF

Simultaneous 18-FDG PET and MR imaging in lower extremity arterial disease.

Front Cardiovasc Med

February 2024

Department of Internal Medicine I, Cardiology and Angiology, School of Medicine and Health, Technical University of Munich, Munich, Germany.

Background: Simultaneous positron emission tomography (PET) and magnetic resonance imaging (MRI) is a novel hybrid imaging method integrating the advances of morphological tissue characterization of MRI with the pathophysiological insights of PET applications.

Aim: This study evaluated the use of simultaneous 18-FDG PET/MR imaging for characterizing atherosclerotic lesions in lower extremity arterial disease (LEAD).

Methods: Eight patients with symptomatic stenoses of the superficial femoral artery (SFA) under simultaneous acquisition of 18-FDG PET and contrast-enhanced MRI using an integrated whole-body PET/MRI scanner.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!